drugset
drugset / Trial / NCT03119467

Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas

NCT03119467 ↗

Phase 1 Terminated 21 enrolled Rhizen Pharmaceuticals SA
NaSingle-groupOpen-labelTreatment

Summary

A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients with Relapsed or Refractory Lymphomas

Timeline

Start
2017-05-11
Primary completion
2019-11-29
Completion
2019-12-19

Outcome

Outcome not reported

Stopped: “Study has been stopped after reviewing PK and safety results”

Drugs

EvaluationDrugModalityDoseRoute
Subject RP4010 Unknown 25 mg —

Indications

lymphoma